Sedana Medical Q3 Sales Rise 7% at Constant FX; FDA Accepts NDA
Q3 net sales were SEK 44.2 million, up 7% at constant FX. The FDA accepted the NDA and set an April 16, 2027 PDUFA date. Year-to-date EBITDA improved to negative SEK 7.1 million from negative SEK 10.2 million; cash was SEK 40 million with SEK 50 million in credit available.
Sedana Medical AB (publ) reported Q3 net sales of SEK 44.2M, a 7% increase at constant FX. The FDA accepted the company’s NDA, with a PDUFA date of Apr 16, 2027. Group YTD EBITDA improved to -SEK 7.1M from -SEK 10.2M. Cash totaled SEK 40M, and SEK 50M in credit was available.